1608 W. Campbell Avenue
Neurogastrx is a private biopharmaceutical company focused on discovering and developing transformative therapies for gastrointestinal disorders affecting the enteric nervous system.
CEO: Jim O'Mara
Chairman of the Board: Klaus Veitinger
CSO: Cyril De Colle, PhD
CFO: Glenn Goddard
3 articles with Neurogastrx
Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.
Neurogastrx, Inc., announced today that it has entered into an exclusive license agreement with Daewoong Pharmaceutical Co., Ltd., of Seoul, South Korea, for the development and commercialization of fexuprazan, an investigational novel potassium-competitive acid blocker (P-CAB) for the treatment of erosive esophagitis (EE) and other acid-related conditions.
10/22/2018Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.
The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners.